vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and BTCS Inc. (BTCS). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $7.1M, roughly 1.5× BTCS Inc.). On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 205.5%). Over the past eight quarters, BTCS Inc.'s revenue compounded faster (296.4% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs BTCS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $7.1M |
| Net Profit | $2.5M | — |
| Gross Margin | — | 12.4% |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | — |
| Revenue YoY | 522.2% | 205.5% |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $-1.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $7.1M | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | $10.7M | $2.8M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $739.2K | ||
| Q2 24 | — | $561.2K | ||
| Q1 24 | — | $451.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | $65.6M | ||
| Q2 25 | $2.5M | $3.9M | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-9.0M | ||
| Q2 24 | — | $-6.7M | ||
| Q1 24 | — | $12.3M |
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | — | -2.9% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 69.9% | ||
| Q1 24 | — | 64.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1328.1% | ||
| Q2 25 | 23.5% | 140.0% | ||
| Q1 25 | — | -1022.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1223.0% | ||
| Q2 24 | — | -1198.9% | ||
| Q1 24 | — | 2715.3% |
| Q4 25 | — | $-1.58 | ||
| Q3 25 | — | $1.30 | ||
| Q2 25 | $0.01 | $0.14 | ||
| Q1 25 | — | $-0.86 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | — | $-0.56 | ||
| Q2 24 | — | $-0.43 | ||
| Q1 24 | — | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $1.5M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $139.4M |
| Total Assets | $103.3M | $214.6M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.5M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | $37.4M | $639.2K | ||
| Q1 25 | — | $269.9K | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $254.5K | ||
| Q2 24 | — | $536.7K | ||
| Q1 24 | — | $670.6K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $139.4M | ||
| Q3 25 | — | $225.4M | ||
| Q2 25 | $83.0M | $31.1M | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $33.1M | ||
| Q1 24 | — | $39.3M |
| Q4 25 | — | $214.6M | ||
| Q3 25 | — | $298.9M | ||
| Q2 25 | $103.3M | $40.8M | ||
| Q1 25 | — | $21.0M | ||
| Q4 24 | — | $38.2M | ||
| Q3 24 | — | $26.5M | ||
| Q2 24 | — | $33.8M | ||
| Q1 24 | — | $39.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-9.8M |
| Free Cash FlowOCF − Capex | — | $-9.8M |
| FCF MarginFCF / Revenue | — | -138.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-15.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-9.8M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | $-15.7M | $-1.3M | ||
| Q1 25 | — | $-1.9M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | $-695.2K | ||
| Q2 24 | — | $-924.1K | ||
| Q1 24 | — | $-769.0K |
| Q4 25 | — | $-9.8M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | — | $-1.9M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -138.1% | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | -48.2% | ||
| Q1 25 | — | -112.7% | ||
| Q4 24 | — | -152.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | -6.24× | -0.34× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
BTCS
| Builder Plus | $5.9M | 83% |
| Other | $1.2M | 17% |
